



RESEARCH ARTICLE

Clinical Efficacy of Misoprostol in Second Trimester Abortion

Shah AC^{1*}, Shah S², Modi A³, Modi R⁴

¹Assistant Professor, Sheth L.G. Hospital, AMC MET Medical College, Ahmedabad, Gujarat, India.

²Professor, Sheth L.G. Hospital, AMC MET Medical College, Ahmedabad, Gujarat, India.

³Third year PG Resident, Department of Obst. and Gynecology, N.H.L. Municipal Medical College, Ahmedabad, Gujarat, India.

⁴First year PG Resident, Department of Pharmacology, S.B.K.S. and M.I.R.T., Sumandeep Vidyapeeth, Vaghodia, Gujarat, India.

Manuscript No: IJPRS/V3/I1/00110, Received On: 05/03/2014, Accepted On: 10/03/2014

ABSTRACT

Study was conducted from February, 2013 to April, 2013 at Sheth L.G. Hospital, AMC MET Medical College, Ahmedabad, Gujarat. A total of 50 patients, at 13-28 weeks of gestation, requiring termination of pregnancy were included in study protocol. Major indications for termination of pregnancy were intrauterine death of fetus, severe preclamsia and congenital anomaly. Each woman received first dose of 400 µg of misoprostol vaginally and were repeated every 4 hours as per need till induction of abortion. Abortion was seen in 13(26%) patients with induction to delivery period of less than 12 hour. Out of 50 women, 20 (40%) have been aborted in between 12 to 16 hours of drug administration. Whereas in 10(%) women, termination of pregnancy was found in between 16 to 20 hours. Though in 7(14%) patients, pregnancy was terminated after 20 hours. It was found complete and incomplete abortion in 43(86%) and 7(14%) cases, respectively. Observed side effects included G.I. disturbances and fever in 10(20%) and 15(30%) cases, respectively. Overall per vaginal administration of misoprostol was found clinically safe, efficacious and a cost effective for induction of second trimester abortion.

KEYWORDS

Efficacy, Misoprostol, Abortion, Second-Trimester

INTRODUCTION

Termination of pregnancy for various, fetal as well as maternal conditions, is a common obstetrical problem. Abortion is defined as 'termination of pregnancy by any means before the fetus is viable'. Viability is now considered to be reached at 23-24 weeks of gestation. Second trimester or mid-trimester is a period ranging from 13 to 28 weeks? Induction of abortion, the single most common procedure

performed over women worldwide, needs meticulous and effective care. Many studies have been done for 2nd trimester abortion; still there is search for safer and cost effective method for second trimester abortion. Second trimester abortion gives a psychological blow to the patient. It is associated with more abdominal pain and it persists for longer time till abortion completes.

Misoprostol was used successfully for induction of second trimester abortion.¹⁻³ Misoprostol is a synthetic PGE1 analogue (15-deoxy-16-hydroxy-16-methyl PGE1) which induces cervical ripening as well as strong uterine

***Address for Correspondence:**

Dr. Akshay C. Shah

Assistant Professor,
Sheth L.G. Hospital, AMC MET Medical College,
Ahmedabad, Gujarat, India.

E-Mail Id: drshahakshay@yahoo.com

contractions and leads to expulsion of a pregnancy. Misoprostol can be absorbed by many routes, and has different pharmacokinetic properties in each route. Misoprostol is absorbed the fastest via sublingual route. Orally, it is slowly absorbed than sublingual, but faster than vaginal/rectal routes.

The vaginal or rectal route leads to a lower peak level of MPA (misoprostol acid), but has a much slower elimination curve.⁴ There are some reports that repeated doses of vaginal misoprostol may be inferior to repeated buccal/sublingual doses due to vaginal bleeding and subsequent degradation of vaginal absorption.⁴⁻⁶

The above information is important because it can predict the side effect profile and speed of onset of the drug. Oral or sublingual drug administration leads to higher levels and speedy onset of drug action, but associated with greater side effect (predominantly fever and chills). Hence it is inevitable to study misoprostol with per vaginal administration for induction of abortion for induction of second trimester abortion.

MATERIALS AND METHOD

This study was carried out at Sheth L.G. Hospital, AMC MET Medical College, Ahmedabad, Gujarat. In present study, fifty female patients having had medical indications for termination of pregnancy were included. All of them were having pregnancy of 13-28 weeks. Abortion was needed in all the cases either due to medical reasons or due to pregnancy failure. All the patients underwent per abdomen, per speculum and per vaginal examination and then ultrasonography was done.

All the patients were given 400 µg misoprostol drug which was kept per vaginally and repeated at every 4 hours up to the induction of abortion. Some patients were excluded from the misoprostol treatment study. The exclusion criteria were patients having previous uterine scar, history of allergy to misoprost, excessive bleeding from vagina and or chorioamnionitis. Statistical analysis was performed using

Microsoft excel and values are expressed as percentage.

RESULTS

A total of 50 pregnant women having history of 13-28 weeks gestation period were taken in the study where in abortion was needed either due to medical reasons or due to pregnancy failure. Major indication for termination of pregnancy was intrauterine death of fetus (in 76 % cases) whereas severe preclamsia and congenital anomaly were found in 14 and 10 % of cases, respectively (Table 1).

In 7 (14%) cases, maximum dose of misoprostol(>2000 µg) was required whereas in 13 (26%) cases, minimum dose of misoprostol (< 1200 µg) was required. 20 (40%) women got aborted successfully with the misoprostol dose of 1200-1600 µg whereas 10 (20%) women required 1600-2000 µg dose of misoprostol (Table 2).

Time interval between inductions to abortion was varied from <12 to >20 hours (Table 2). In majority of the patients (43 cases; 86%) abortion was found complete whereas in only 7(14%) cases, in was found incomplete. None of the patients died due to any complications. Some minor complications like G.I. side effects and fever were found in 10 (20%) and 15 (30%) cases, respectively.

Table 1: Indication for termination of pregnancy

No.	Indication	No. of cases	%
1	Intrauterine death	38	76%
2	Severe preclampsia	7	14%
3	Congenital anomaly	5	10%

Table 2: Total dose of misoprostol required for termination of pregnancy and time interval between inductions to abortion

Dose (in µg)	Interval between induction to abortion(hrs)	No of patients	Percentage
<1200	<12	13	26%
1200-1600	12-16	20	40%
1600-2000	16-20	10	20%
>2000	>20	7	14%

DISCUSSION

Termination of pregnancy by induced abortion is practiced worldwide. Induced abortion, either elective or therapeutic termination of viable pregnancy, is one of the most ancient procedures. Worldwide midterm abortion constitutes 10-15% of all induced abortion but is responsible for two-thirds of all major complications.⁷ Misoprostol is a synthetic PGE₁ analogue, initially developed for the prevention and treatment of peptic ulcer and later used as an abortifacient. It has several advantages over other PGs. It is cheap, efficacious, stable at room temperature, can be stored for a long time and having few side effects.

Clinical efficacy of misoprostol is more while administering vaginally than orally.⁸⁻¹² In present study, results of using metoprostol by vaginal route are highly encouraging with least side effects and complications. In this study the successful abortion rate was 86%. Previously the success rate of induction of abortion was found ranging from 68 to 83% with misoprostol given per vaginally.¹³⁻¹⁴

CONCLUSION

Misoprostol is an excellent drug for abortion of pregnancy during second trimester as it causes

high percent of complete abortion, within shorter time and with lesser chance of complications and side effects. So, this drug can be safely and effectively used in second trimester for abortion provided exclusion criteria are fulfilled. This drug has advantages like it is cost effective, effects are reversible when kept in vagina, and side effects are few and mild.

REFERENCES

1. Tang, O. S., Schweer, H., Seyberth, H. W., Lee, S. W., & Ho, P. C. (2002). Pharmacokinetics of different routes of administration of misoprostol. *Human Reproduction*, 17(2), 332-336.
2. Ho, P. C., Blumenthal, P. D., Gemzell-Danielsson, K., Gomez Ponce de Leon, R., Mittal, S., & Tang, O. S. (2007). Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks. *International Journal of Gynecology & Obstetrics*, 99, S178-S181.
3. Gómez Ponce de León, R., Wing, D., & Fiala, C. (2007). Misoprostol for intrauterine fetal death. *International Journal of Gynecology & Obstetrics*, 99, S190-S193.
4. Goldberg, A. B., Greenberg, M. B., & Darney, P. D. (2001). Misoprostol and pregnancy. *New England Journal of Medicine*, 344(1), 38-47.
5. Collins, P. W., Pappo, R., & Dajani, E. Z. (1985). Chemistry and synthetic development of misoprostol. *Digestive diseases and sciences*, 30(11), 114S-117S.
6. Ziemann, M., Fong, S. K., Benowitz, N. L., Banskter, D., & Darney, P. D. (1997). Absorption kinetics of misoprostol with oral or vaginal administration. *Obstetrics & Gynecology*, 90(1), 88-92.
7. World Health Organization. (1997). *Medical methods for termination of pregnancy: report of a WHO Scientific Group* (No. 871). World Health Organization.
8. Dickinson, J. E., & Evans, S. F. (2003). A Comparison of Oral Misoprostol with

Vaginal Misoprostol Administration in Second-Trimester Pregnancy Termination for Fetal Abnormality. *Obstetrics & Gynecology*, 101(6), 1294-1299.

9. Ho, P. C., Ngai, S. W., Liu, K. L., Wong, G. C. Y., & Lee, S. W. H. (1997). Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy. *Obstetrics & Gynecology*, 90(5), 735-738.
10. Ziemann, M., Fong, S. K., Benowitz, N. L., Banskter, D., & Darney, P. D. (1997). Absorption kinetics of misoprostol with oral or vaginal administration. *Obstetrics & Gynecology*, 90(1), 88-92.
11. Bebbington, M. W., Kent, N., Lim, K., Gagnon, A., Delisle, M. F., Tessier, F., & Wilson, R. D. (2002). A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. *American journal of obstetrics and gynecology*, 187(4), 853-857.
12. Schaff, E. A., Fielding, S. L., & Westhoff, C. (2002). Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. *Contraception*, 66(4), 247-250.
13. Munthali, J., & Moodley, J. (2001). The use of misoprostol for mid-trimester therapeutic termination of pregnancy. *Tropical doctor*, 31(3), 157-161.
14. Herabutya, Y., Chanrachakul, B., & Punyavachira, P. (2001). Second trimester pregnancy termination: a comparison of 600 and 800 micrograms of intravaginal misoprostol. *Journal of Obstetrics and Gynaecology Research*, 27(3), 125-128.

